Coumarin-suberoylanilide hydroxamic acid as a fluorescent probe for determining binding affinities and off-rates of histone deacetylase inhibitors

Analytical Biochemistry

Volumn 408, Issue 2, 2011, Pages 309-315

  Singh, Raushan K ^a   Mandal, Tanmay ^a   Balasubramanian, Narayanaganesh ^a   Cook, Gregory ^a   Srivastava, D K ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Binding affinity; Dissociation off rate; Fluorescent probe; Histone deacetylase; Inhibitor

Indexed keywords

AMINO ACIDS; DISEASES; DISSOCIATION; ENERGY TRANSFER; ENZYMES; FLUORESCENCE; FLUORESCENCE SPECTROSCOPY; PROBES; SYNTHESIS (CHEMICAL);

BINDING AFFINITIES; FLUORESCENCE EMISSION INTENSITY; FLUORESCENCE ENERGY TRANSFER; FLUORESCENT PROBES; HISTONE DEACETYLASE INHIBITOR; HISTONE DEACETYLASES; INHIBITOR; SUBEROYLANILIDE HYDROXAMIC ACIDS;

BINDING ENERGY;

COUMARIN; HISTONE DEACETYLASE INHIBITOR; TRYPTOPHAN; VORINOSTAT;

ARTICLE; BINDING AFFINITY; ENERGY TRANSFER; FLUORESCENCE; POLARIZATION; PRIORITY JOURNAL; SYNTHESIS;

EID: 78149415398     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2010.08.040     Document Type: Article

References (40)

1. Strahl D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
2. Marmorstein R. Protein modules that manipulate histone tails for chromatin regulation. Nat. Rev. Mol. Cell Biol. 2001, 2:422-432.
3. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389:349-352.
4. Roth S.Y., Denu J.M., Allis C.D. Histone acetyltransferases. Annu. Rev. Biochem. 2001, 70:81-120.
5. Allfrey V.G., Faulkner R., Mirsky A.E. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl. Acad. Sci. USA 1964, 51:786-794.
6. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5:769-784.
7. Ma X., Ezzeldin H.H., Diasio R.B. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009, 69:1911-1934.
8. Grant C., Rahman F., Piekarz R., Peer C., Frye R., Robey R.W., Gardner E.R., Figg W.D., Bates S.E. Romideps: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev. Anticancer Ther. 2010, 10:997-1008.
9. Marks P.A., Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 2007, 25:84-90.
10. Gregoretti I.V., Lee Y., Goodson H.V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 2004, 338:17-31.
11. Holbert M.A., Marmorstein R. Structure and activity of enzymes that remove histone modifications. Curr. Opin. Struct. Biol. 2005, 15:673-680.
12. Blander G., Guarente L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 2004, 73:417-435.
13. de Ruijter A.J.M., van Gennip A.H., Caron H.N., Kemp S., van Kuilenburg A.B.P. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003, 370:737-749.
14. Wegener D., Hildmann C., Schwienhorst A. Recent progress in the development of assays suited for histone deacetylase inhibitor screening. Mol. Genet. Metab. 2003, 80:138-147.
15. Wegener D., Wirsching F., Riester D., Schwienhorst A. A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. Chem. Biol. 2003, 10:61-68.
16. Wegener D., Hildmann C., Riester D., Schwienhorst A. Improved fluorogenic histone deacetylase assay for high-throughput screening applications. Anal. Biochem. 2003, 321:202-208.
17. Riester D., Hildmann C., Schwienhorst A., Meyer-Almes F. Histone deacetylase inhibitor assay based on fluorescence resonance energy transfer. Anal. Biochem. 2007, 362:136-141.
18. Riester D., Hildmann C., Haus P., Galetovic A., Schober A., Schwienhorst A., Meyer-Almes F. Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases. Bioorg. Med. Chem. Lett. 2009, 19:3651-3656.
19. Mazitschek R., Patel V., Wirth D.F., Clardy J. Development of a fluorescence polarization based assay for histone deacetylase ligand discovery. Bioorg. Med. Chem. Lett. 2008, 18:2809-2812.
20. Schultz B.E., Misialek S., Wu J., Tang J., Conn M.T., Tahilramani R., Wong L. Kinetics and comparative reactivity of human class I and class IIb histone deacetylases. Biochemistry 2004, 43:11083-11091.
21. Krogsgaard M., Prado N., Adams E.J., He X., Chow D., Wilson D.B., Garcia K.C., Davis M.M. Evidence that structural rearrangements and/or flexibility during TCR binding can contribute to T cell activation. Mol. Cell 2003, 12:1367-1378.
22. Vannini A., Volpari C., Filocamo G., Casavola E.C., Brunetti M., Renzoni D., Chakravarty P., Paolini C., De Francesco R., Gallinari P., Steinkühler C., Di Marco S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. USA 2004, 101:15064-15069.
23. Somoza J.R., Skene R.J., Katz B.A., Mol C., Ho J.D., Jennings A.J., Luong C., Arvai A., Buggy J.J., Chi E., Tang J., Sang B., Verner E., Wynands R., Leahy E.M., Dougan D.R., Snell G., Navre M., Knuth M.W., Swanson R.V., McRee D.E., Tari L.W. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004, 12:1325-1334.
24. Cabrita L.D., Dai W., Bottomley S.P. A family of E. coli expression vectors for laboratory scale and high throughput soluble protein production. BMC Biotechnol. 2006, 6:1-8.
25. Gediya L.K., Chopra P., Purushottamachar P., Maheshwari N., Njar V.C.O. A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. J. Med. Chem. 2005, 48:5047-5051.
26. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual 2001, Cold Spring Harbor Laboratory Press, New York.
27. Hemanson G.T., Mallia A.K., Smith P.K. Immobilized Affinity Ligand Techniques 1992, Academic Press, San Diego.
28. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
29. Qin L., Srivastava D.K. Energetics of two-step binding of a chromophoric reaction product, trans-3-indoleacryloyl-CoA, to medium-chain acyl-coenzyme-A dehydrogenase. Biochemistry 1998, 37:3499-3508.
30. Morrison J.F. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta 1969, 185:269-286.
31. Bradner J.E., West N., Grachan M.L., Greenberg E.F., Haggarty S.J., Warnow T., Mazitschek R. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 2010, 6:238-243.
32. Banerjee A.L., Swanson M., Roy B.C., Jia X., Haldar M.K., Mallik S., Srivastava D.K. Protein surface-assisted enhancement in the binding affinity of an inhibitor for recombinant human carbonic anhydrase II. J. Am. Chem. Soc. 2004, 126:10875-10883.
33. Wang Z.X. An exact mathematical expression for describing competitive binding of two different ligands to a protein molecule. FEBS Lett. 1995, 360:111-114.
34. Kuzmic P., Moss M.L., Kofron J.L., Rich D.H. Fluorescence displacement method for the determination of receptor-ligand binding constants. Anal. Biochem. 1992, 205:65-69.
35. Kuzmic P. Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase. Anal. Biochem. 1996, 237:260-273.
36. Lackowicz J.R. Principles of Fluorescence Spectroscopy 2006, Springer, New York.
37. Hildmann C., Wegener D., Riester D., Hempel R., Schober A., Merana J., Giurato L., Guccione S., Nielsen T.K., Ficner R., Schwienhorst A. Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases. J. Biotechnol. 2006, 124:258-270.
38. Hahnen E., Eyüpoglu I.Y., Brichta L., Haastert K., Tränkle C., Siebzehnrübl F.A., Riessland M., Hölker I., Claus P., Romstöck J., Buslei R., Wirth B., Blümcke I. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J. Neurochem. 2006, 98:193-202.
39. Hahnen E., Hauke J., Tränkle C., Eyüpoglu I.Y., Wirth B., Blümcke I. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin. Invest. Drugs 2008, 17:1-16.
40. Fatkins D.G., Zheng W. A spectrophotometric assay for histone deacetylase 8. Anal. Biochem. 2008, 372:82-88.